HC Wainwright & Co. Maintains Buy on Humacyte, Raises Price Target to $4

Benzinga Newsdesk www.benzinga.com Positive 81.3%

Neg 0% Neu 0% Pos 81.3%

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Humacyte (NASDAQ:HUMA) with a Buy and raises the price target from $3 to $4.